TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06379789: A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 130 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$525,300

Rescue Site Savings

+$350,200

Unlock Full NCT06379789 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06379789 Rescue Dossier →